Heterocyclic compound and antitumor agent containing the...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C544S112000, C544S114000

Reexamination Certificate

active

11478647

ABSTRACT:
The present invention relates to heterocyclic compounds represented by the formula I or pharmaceutically acceptable salts thereof and antitumor agents containing the heterocyclic compounds as effective components:wherein X represents nitrogen atom or CH; R1represents CHnF3-n(wherein n is 1 or 2), hydroxy C1-C6alkyl, NHR6[wherein R6represents hydrogen atom or COR (wherein R represents hydrogen atom, C1-C6alkyl or C1-C6alkoxy)]; R2represents morpholino (which may be substituted with one to four C1-C6alkyl), thiomorpholino, piperidino, pyrrolidinyl (which may be substituted with hydroxy C1-C6alkyl), oxazolidinyl (which may be substituted with one or two C1-C6alkyl) or tetrahydro-1,4-thiazin-1-oxo-4-yl; R3and R4each represent hydrogen atom or C1-C6alkyl; and R5represents hydrogen atom, amino or hydroxyl.

REFERENCES:
patent: 3308122 (1967-03-01), Tolkmith
patent: 5489591 (1996-02-01), Kobayashi et al.
patent: 5852019 (1998-12-01), Ejima et al.
patent: 6251900 (2001-06-01), Kawashima et al.
patent: 7071189 (2006-07-01), Kawashima et al.
patent: 2004/0116421 (2004-06-01), Kawashima et al.
patent: 2006/0009440 (2006-01-01), Kawashima et al.
patent: 0 240 854 (1987-10-01), None
patent: 0 640 599 (1995-03-01), None
patent: 49-17677 (1974-05-01), None
patent: 56-55302 (1981-05-01), None
patent: 62-240673 (1987-10-01), None
patent: WO 93/17009 (1993-09-01), None
patent: WO 96/10024 (1996-04-01), None
patent: 99/5138 (1999-02-01), None
patent: 00/43385 (2000-07-01), None
patent: WO 02/088112 (2002-11-01), None
patent: WO 2004/037812 (2004-05-01), None
patent: WO 2005/095389 (2005-10-01), None
U.S. Appl. No. 11/404,078, filed Apr. 14, 2006, Yaguchi, et al.
Bonny L. Johnson, et al., “Hexamethylmelamine in Alkylating Agent-Resistant Ovarian Carcinoma”, Cancer, vol. 42, Nov. 1978, pp. 2157-2161.
Toshiyuki Matsuno, et al., “Synthesis and Aromatase-Inhibitory Activity of Imidazolyl-1,3,5-triazine Derivatives”, Chem. Pharm. Bull., vol. 45, No. 2, Feb. 1997, pp. 291-296.
Shin-Ichi Yaguchi, et al., The 64thAnnual Meeting Abstract of the Japanese Cancer Association, W-018, and PA2-0729-PA20732, Sep. 2005 (with English abstracts).
Shin-ichi Yaguchi, et al., The 96thAnnual Meeting Abstract of American Association for Cancer Research, 1691, C65 and C239, Nov. 2005, 6 pages.
Shin-ichi Yaguchi, et al., “Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor”, Journal of the National Cancer Institute, vol. 98, No. 8, Apr. 19, 2006, pp. 545-556.
Shin-ichi Yaguchi, et al., “In Vitro Cytotoxicity of Imidazolyt-1,3,5-triazine Derivatives”, Biol. Pharm. Bull., vol. 20, No. 6, Jun. 1997, pp. 698-700.
Yuichi Iino, et al., “Antitumor Effects of SEF19, a New Nonsteroidal Aromatase Inhibitor, on 7,12-Dimethylbenz [a] anthracene-Induced Mammary Tumors in Rats”, Anticancer Research, vol. 18, 1998, pp. 171-176.
Takao Yamori, et al., “A novel Phosphatidylinositol 3-kinase Inhibitor, ZSTK474, and its Preclinical Activity”, the 10thInternational Symposium on Cancer Chemotherapy, Jan. 2006, 2 pages.
U.S. Appl. No. 10/594,994, filed Sep. 29, 2006, Kawashima, et al.
Chem. Pharm. Bull vol. 48, No. 11, pp. 1778-1781, 2000.
Toshiyuki Matsuno, et al., Chem. Pharm. Bull., vol. 48, No. 11, pp. 1778-1781, 2000.
Cecil Textbook of Medicine, Edited by Bennet, J.C., and Plum F., 20thEdition, vol. 1, pp. 1004-1010 (1996).
Connor, et al., Fundamental and Applied Toxicology, vol. 30(1):93-101 (1996).
Coley, et al. Anticancer Research 16(4A); pp. 1851-1855 (1996).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Heterocyclic compound and antitumor agent containing the... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic compound and antitumor agent containing the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compound and antitumor agent containing the... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3862699

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.